|
|
 |
|
|
|
| History |
| MHC Biologics LLC was founded in May 2007 to focus on clinical applications of a suite of immunology tools developed in the laboratories of Dr. Jon Weidanz (Texas Tech University Pharmacy School and Receptor Logic, Inc.) and Dr. William Hildebrand (Oklahoma University Health Science Center and Pure Vaccine Solutions, Inc.). The primary focus of clinical efforts is on developing novel therapeutics, including therapeutic vaccines for cancer and other diseases. |
|
| Management |
|
ETI Management |
| Gregory Pogue, Ph.D. |
| President and Managing Director |
Gregory Pogue serves as Vice President of Business Development for Emergent Technologies, Inc., and currently serves on the management team for ETI portfolio company MHC Biologics as President and Managing Director.
As Vice President of Business Development at Emergent Technologies, Dr. Pogue is responsible for evaluating the commercial potential of new technologies, determining both technical and market trajectories, and building partnerships to effectively commercialize products. Dr. Pogue brings over twenty years of experience in biologic development, spanning research management, biologic regulation, and intellectual property development and licensing. Dr. Pogue most recently served as Licensing Associate for the University of Texas at Austin where he negotiated licenses with companies ranging from newly formed startups to Fortune 500 enterprises. Before coming to Texas, Dr. Pogue served as Vice President of Research and Development at Large Scale Biology Corporation (LSBC), where he managed a broad development program involving product development and preclinical and clinical testing of numerous lead compounds, including two receiving Orphan Drug Designation from the US FDA and 16 successfully completing early clinical trials. He also developed licensing and R&D contracts with corporate, academic, and government entities and supervised collaborative research relationships. Before joining LSBC, Dr. Pogue worked in the U.S. FDA's Center for Biologics Research and Evaluation as a scientist with Investigational New Drug and Biological Licensing Application review responsibilities. He holds a B.S. from Midwestern State University and a Ph.D. from Texas A&M University. Pogue has published numerous original scientific articles and reviews, is an inventor on multiple U.S. patents, and is a frequent invited speaker at national and international scientific meetings. |
|
Portfolio Company Advisors |
| Donald Capra, M.D. |
| Strategic Technical Advisor |
| Dr. Capra was the President of the Oklahoma Medical Research Foundation after leaving the University of Texas Southwestern Medical Center in Dallas, Texas in 1997, where he served as professor of microbiology and internal medicine and was the Edwin L. Cox Distinguished Chair in Immunology and Genetics. He joined UT Southwestern in 1974 and in 1994 was named Director of Southwestern’s Molecular Immunology Center. Dr. Capra is well known for his studies of antibody genes and how they are mutated in autoimmune disorders. His early work on the relationship of the hypervariable regions of antibodies to the antibody combining site and idiotype of an immunoglobulin molecule are well known. He has published over 400 papers in the scientific literature, edited four books including a textbook of Immunology, and co-authored a book “The Antibody Enigma”. |
|
| George Peoples, M.D. |
| Strategic Clinical Advisor |
| Dr. Peoples is a clinician and co-inventor of the core technology of Apthera. Dr. Peoples has been named to direct the newly created United States Military Cancer Institute’s Clinical Trials Program which is headquartered at Brooke Army Medical Center in Ft. Sam Houston, TX. Dr. Peoples previously served as Chief of Surgical Oncology at Walter Reed Army Medical Center (WRAMC). He continues to serve as the Director of the Cancer Vaccine Development Laboratory at the Uniformed Services University of the Health Sciences. |
|
MHC Biologics, LLC, is an Emergent Technologies Inc. (ETI) portfolio company and ETI provides all management services and operations support.
About Emergent Technologies, Inc.
Headquartered in Austin, Texas, Emergent Technologies, Inc. (ETI) is a life sciences technology investment and management company which provides early stage funding and development for scientific discoveries originating at universities and research institutions. The Company creates value by transforming scientific breakthroughs into technology platforms with multiple applications. ETI's unique innovation process enables the Company to select promising scientific discoveries for development, maximize the value of intellectual property and manage both cost and risk associated with the commercial development of early stage technologies. ETI is dedicated to turning research into revenue and, in the process, introducing compelling solutions to meet important market needs. For more information, visit the company website www.etibio.com |
|
|
 |
